Table 2. Comparison of clinical and laboratory features in AML patients with low- and high risk groups.
| Patients parameters | Risk score group | ||
|---|---|---|---|
| Low-risk group (n=39) | High-risk group (n=49) | P-value | |
| Sex, male/female | 18/21 | 19/30 | 0.521 |
| Median age, years (range) | 54 (21–86) | 55 (24–93) | 0.551 |
| Median WBC, ×109/l (range) | 7.8 (0.3–185.4) | 41.4 (1.1–528) | 0.004 |
| Median Hb, g/l (range) | 78.0 (34.0–131.0) | 75.0 (42.0–138.0) | 0.831 |
| Median PLTs, ×109/l (range) | 39.5 (7.0–118.0) | 52.0 (12.0–264.0) | 0.017 |
| BM blasts, % (range) | 34.5 (1.0–90.0) | 62.0 (3.0–97.7) | 0.011 |
| CR (+/−) | 23/14 | 17/30 | 0.027 |
| FAB | 0.005 | ||
| M0 | 0 | 0 | |
| M1 | 1 | 6 | |
| M2 | 16 | 16 | |
| M3 | 14 | 6 | |
| M4 | 4 | 17 | |
| M5 | 3 | 4 | |
| M6 | 1 | 0 | |
| 2016 WHO classification | 0.100 | ||
| AML with t(8;21) (q22;q22.1) | 3 | 4 | |
| AML with PML-RARA | 14 | 6 | |
| AML with mutated NPM1 | 4 | 3 | |
| AML with biallelic mutations of CEBPA | 2 | 0 | |
| AML without maturation | 0 | 4 | |
| AML with maturation | 9 | 11 | |
| Acute myelomonocytic leukemia | 4 | 17 | |
| Acute monoblastic/monocytic leukemia | 2 | 4 | |
| Pure erythroid leukemia | 1 | 0 | |
| Karyotype classification | 0.055 | ||
| Favorable | 17 | 10 | |
| Intermediate | 16 | 27 | |
| Poor | 3 | 10 | |
| No data | 3 | 2 | |
| Karyotype | 0.009 | ||
| normal | 15 | 16 | |
| t(8;21) | 3 | 4 | |
| t(15;17) | 14 | 6 | |
| Others | 3 | 11 | |
| Complex | 1 | 10 | |
| No data | 3 | 2 | |
| Gene mutation | |||
| CEBPA (+/−) | 5/32 | 2/42 | 0.237 |
| NPM1 (+/−) | 4/33 | 3/41 | 0.551 |
| FLT3-ITD (+/−) | 3/34 | 7/37 | 0.332 |
| c-KIT (+/−) | 1/36 | 1/43 | 1.000 |
| IDH1/2 (+/−) | 1/36 | 2/42 | 1.000 |
| DNMT3A (+/−) | 2/35 | 5/39 | 0.445 |